150
Views
35
CrossRef citations to date
0
Altmetric
Review

Improved understanding of factors driving methicillin-resistant Staphylococcus aureus epidemic waves

&
Pages 205-217 | Published online: 04 Jul 2013

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) remains one of the most important causes of nosocomial infections worldwide. Since the global spread of MRSA in the 1960s, MRSA strains have evolved with increased pathogenic potential. Notably, some strains are now capable of causing persistent infections not only in hospitalized patients but also in healthy individuals in the community. Furthermore, MRSA is increasingly associated with infections among livestock-associated workers, primarily because of transmission from animals to humans. Moreover, many MRSA strains have gained resistance to most available antibiotics. In this review, we will present current knowledge on MRSA epidemiology and discuss new endeavors being undertaken to understand better the molecular and epidemiological underpinnings of MRSA outbreaks.

Introduction

Infection caused by bacterial pathogens is a global problem. In many cases, bacterial resistance to antimicrobial agents may considerably complicate treatment.Citation1 Several infectious strains have acquired resistance toward most available antibiotics, which warrants global surveillance and antimicrobial stewardship in addition to increased research efforts to understand the mechanisms underlying pathogenesis and antimicrobial resistance. This is especially true in the case of methicillin-resistant Staphylococcus aureus (MRSA) which is one of the most prominent pathogens associated with hospital-, community-, and livestock-associated infections.Citation2 In this review, we discuss the epidemiology, pathophysiology, and impact on clinical practice of MRSA infections. In addition to this, we highlight important recent research efforts aimed at bettering understanding the key factors that drive MRSA epidemics.

History of MRSA

S. aureus has been associated with human infections since prehistoric times.Citation3 Due to its prominence as a health-care-related pathogen, it has been a cause of serious concern for clinicians for over a century.Citation4 Following the introduction of penicillin in the 1940s, the first antimicrobial drug of its kind showing high effectiveness against staphylococcal infections, S. aureus developed penicillin resistance within a few months.Citation5,Citation6 The molecular determinant responsible for penicillin resistance was shown to be a plasmid-encoded β-lactamase gene capable of cleaving the β-lactam ring of penicillin.Citation7,Citation8 Within about two decades, penicillin resistance in S. aureus became a global problem.Citation9

Methicillin, a semisynthetic derivative of penicillin that is resistant to cleavage by β-lactamase, was introduced into clinical use in 1959. Soon afterwards, infections caused by penicillin-resistant strains sharply declined.Citation10 However, within just 2 years following the introduction of methicillin, the first MRSA strains were isolated in hospitals in the UK.Citation11 Thereafter, MRSA became endemic worldwide.Citation4 The molecular determinant of methicillin resistance in MRSA was later shown to be a mobile genetic element (MGE), staphylococcal chromosome cassette mec (SCCmec),Citation12 which harbors the mecA gene encoding a penicillin-binding protein (PBP2a/PBP2′) with reduced affinity towards methicillin.Citation13,Citation14 As a result, methicillin cannot bind to the bacterial cell efficiently, leading to reduced capacity to inhibit bacterial cell-wall synthesis.

Of note, the term MRSA is used loosely, since methicillin sensu stricto is no longer applied in health-care settings. According to the Centers for Disease Control and Prevention, the definition of MRSA spans resistance of S. aureus not only against methicillin but also other related, more common antibiotics such as oxacillin and amoxicillin. Furthermore, mecA also provides general resistance to many β-lactam antibiotics, such as the penicillins. Moreover, SCCmec elements may also contain genes responsible for resistance to a wide array of antimicrobials besides β-lactams.

Emergence of CA-MRSA and LA-MRSA

While MRSA infections were observed sporadically in the community among individuals who had had recent exposure to health-care settings or had been in close contact with MRSA-infected individuals,Citation15 MRSA was considered to be primarily a health-care-associated threat until the late 1990s. At that time, a dramatic shift in the MRSA target population occurred, as otherwise healthy individuals in the community developed MRSA infections in quickly increasing numbers.Citation2,Citation16Citation18 The first case of community-associated MRSA (CA-MRSA) was reported in 1993 in a remote part of Western Australia lacking any close health-care facility.Citation19 Shortly thereafter, CA-MRSA appeared in the US, causing the deaths of four children in the Upper Midwest region.Citation20,Citation21 The history of the onset of CA-MRSA in the US has been reviewed elsewhere in great detail,Citation2,Citation5,Citation16,Citation17 and thus will not be the subject of further discussion here. Currently, a persistently high number of CA-MRSA infections are being observed, in particular in the US, but also in increasing frequency in other parts of the world, reaching pandemic proportions.Citation16,Citation22,Citation23 The fact that the CA-MRSA epidemic is particularly severe in the US is likely due to the high pathogenic potential of the US epidemic CA-MRSA strain USA300, which is now also spreading to other countries. The superiority of USA300 over other CA-MRSA strains may be due to a specific MGE, termed arginine catabolic mobile element (ACME), which harbors genes involved in pathogen survival on the human skin.Citation24,Citation25

Hospital-associated (HA-) and CA-MRSA are defined based on their distinctive association with the hospital or community settings, respectively. According to the current definition, CA-MRSA infections are those for which the onset of infection is within 48 hours of admission to the hospital with no previous history of hospitalization in the past year, whereas HA-MRSA is defined by the onset of infection occurring after 48 hours of hospital admission.Citation26 The successful transfer of strains from the hospital to the community and vice versa has occurred, leading to “community-acquired hospital onset” and “hospital-acquired community onset” MRSA infections.Citation27,Citation28 For that reason, some authors have suggested that CA-MRSA cannot be clearly distinguished anymore from HA-MRSA.Citation29 However, one has to be aware that the CA-/HA-MRSA definition is clinical, not microbiological. While specific strains are typically associated with CA-MRSA infections, the mere identification of the infective isolate as, for example, USA300 does not make an infection a CA-MRSA infection.

At present, an increasing number of reports from the US and abroad indicate that CA-MRSA strains are gradually replacing HA-MRSA strains in hospitals. Several authors have suggested that this indicates yet another potential epidemiological shift in staphylococcal infections.Citation30Citation32 Nevertheless, the traditional hospital-associated strains, such as those of the USA100 and USA200 lineages, are still highly prevalent in hospitals, indicating that they are well adapted to that setting.Citation33,Citation34

S. aureus has also long been associated with severe infections in a variety of economically important livestock animals, including poultry, pigs, and cattle.Citation35Citation38 MRSA in particular has been increasingly associated with livestock-associated (LA-MRSA) infections over the last 40 years.Citation39Citation42 Although MRSA strains caused widespread infections among livestock animals, they showed distinct host tropism.Citation43,Citation44 However, the notion that S. aureus strains have evolved to thrive within a single speciesCitation45 was recently challenged by reports of LA-MRSA strains infecting livestock-associated workers,Citation46 human-to-poultry-transfer of sequence type (ST)-5 strains,Citation42 and transmission of such strains as USA100, USA300, and USA500 between humans and their companion animals.Citation47Citation53 Thus, the recent breach of the genus barrier by LA-MRSA strains points towards remarkable host adaptability of LA-MRSA and indicates that livestock animals can serve as a reservoir for infections in humans.

Target population, transmission, and pathology of infection

S. aureus is a frequent asymptomatic colonizer of humans. Roughly a third of the human population carries S. aureus, primarily in the nose,Citation54,Citation55 but also in other body parts, such as the nasopharynx, groin, and perineum.Citation56 The occurrence of MRSA colonization in the human population is estimated to be about 1.5%, of which roughly one in six carries a CA-MRSA strain.Citation57,Citation58 Recent epidemiological data suggest that CA-MRSA carriage is on the rise in the human population.Citation59

There are several risk factors for the acquisition of an MRSA infection. Generally, an individual is at high risk for infection from his or her own colonizing strain.Citation60 The transmission of the bacteria from an infected to a noninfected individual takes place either by direct skin-to-skin contact with an infected person or through contaminated fomites in public and household settings.Citation61,Citation62 Poor personal hygiene and a compromised skin barrier are believed to play important roles in developing infection in the community, while underlying conditions such as a compromised immune system increase the risk for MRSA infection during hospitalization. MRSA is prevalent in health-care workers,Citation63 indicating that these workers might serve as a reservoir for the spread of HA-MRSA infections in hospitals. Close contact with infected livestock and companion animals is a direct cause of LA-MRSA infections in humans.Citation64,Citation65

The target population of MRSA infections is diverse. Groups at high risk for CA-MRSA infections include prison inmates, military personnel,Citation66 athletes,Citation62 intravenous drug users,Citation9 and men who have sex with men.Citation67 The elderly, children,Citation68 patients with indwelling medical devices,Citation69 people with underlying disease conditions such as diabetesCitation70 or neutrophil dysfunction,Citation71 HIV/AIDS patients,Citation72,Citation73 and individuals who have had a recent history of influenza are at high risk primarily for HA-MRSA infection.

MRSA disease manifestations are equally diverse with regard to seriousness and scope. Mild-to-severe skin and softtissue infections are among the most common MRSA-related diseases.Citation74 However, serious medical complications, such as dermatitis,Citation75 osteomyelitis,Citation76 necrotizing pneumonia,Citation77 ventilator-associated pneumonia,Citation78 endocarditis,Citation79 and bloodstream infections (BSIs)Citation80 may be caused by MRSA. MRSA-related BSI is the highest cause of mortality in the US among bacterial BSI.Citation81 While most CA-MRSA infections are usually infections of the skin and soft tissues, CA-MRSA may also cause severe infections, such as necrotizing pneumonia or necrotizing fasciitis.Citation74 LA-MRSA infections in livestock animals include leg weakness in boiler chickens, abscess and septicemia in rabbits, dermatitis in pigs, and mastitis in cattle.Citation35,Citation37,Citation38,Citation82

Global epidemic status and economic burden

MRSA is the most prominent cause of nosocomial infections caused by a single bacterial pathogen in the US and many parts of the world.Citation27,Citation83Citation85 It is estimated that about 44% of all hospital-associated infections can be attributed to MRSA.Citation86 Recent estimates suggest that in the US, the mortality due to MRSA infections is higher than that due to HIV/AIDS.Citation87

The severity of infections caused by MRSA is thought to be higher than that caused by methicillin-sensitive S. aureus (MSSA),Citation88 not because MRSA strains are in general more virulent, but because they offer fewer therapeutic options. Mounting evidence suggests that MRSA infections lead to a longer stay in hospitals, which in turn leads to higher costs.Citation89,Citation90 According to recent estimates, general MRSA infections resulted in 1 million extra days of hospitalization in the EU, corresponding to US$570 million of additional costs.Citation86 In the US, the cost per MRSA infection is thought to be $12,000,Citation86,Citation91 and a delay in the diagnosis of MRSA bacteremia attributes to costs ranging between $3,800 and $27,000 per patient.Citation92,Citation93 Furthermore, MRSA-related cases of osteomyelitis,Citation94 outbreaks in neonatal intensive care units,Citation95 and infections of indwelling medical devicesCitation96 appear to be on the rise in hospitals.

CA-MRSA is a significant public health threatCitation97 and considered to be the most frequent cause for visits to emergency rooms in the US.Citation98 Currently, CA-MRSA is endemic in Sri Lanka, Taiwan, People’s Republic of China, the Philippines, Vietnam, Australia, Greece, and the UK, besides the US.Citation4,Citation26,Citation99 Worldwide, most CA-MRSA cases are mild soft-tissue infections, although requirement for hospitalization due to severe adult cases of community-associated skin and soft-tissue infection (SSTI) remains high and is estimated to be between 16% and 44%.Citation100 SSTIs are increasing in frequency in the US,Citation101 mostly because of CA-MRSA and the recurrent nature of CA-MRSA infections.Citation102 Of note, SSTI can serve as a source of BSI and hence higher health-care-related cost per patient.Citation80

Current treatment of MRSA

The treatment of MRSA infections is becoming increasingly more complicated due to increasing resistance to antimicrobials and strain diversity. Thus, treatment of MRSA infections is gradually getting geared towards personalized therapy.

In general, therapy for serious MRSA infections involves a multistep process. At first, debridement of the infecting MRSA strain is required, which includes drainage of the contaminated tissue or removal of the infected medical device. Prompt debridement or removal of the infection foci improves the outcomeCitation103,Citation104 and prevents the relapse of infection.Citation104,Citation105 Along with debridement, laboratory tests are performed on the infecting bacterial strain to determine its antibiogram (ie, antibiotic susceptibility). The antibiogram dictates the type of antimicrobial therapy. The Infectious Disease Society of America (IDSA) has set forth a detailed methodological guideline for clinical care of MRSA infections.Citation106

Due to their efficiency, β-lactams are the antibiotics of first choice for staphylococcal infections. However, with MRSA rates becoming increasingly higher and less than 5% of clinical strains being sensitive to penicillins,Citation4 the treatment of S. aureus infection now relies increasingly on non-β-lactam-based antibiotics.Citation107 Although vancomycin is inferior to β-lactam drugsCitation108 in terms of potency in sterilizing the blood,Citation109,Citation110 and toxic effects to kidneys,Citation111 it is the preferred drug for the treatment of MRSA infections.Citation112 Unfortunately, resistance to vancomycin already exists. According to the Clinical and Laboratory Standards Institute, vancomycin-sensitive S. aureus, vancomycin-intermediate S. aureus (VISA), and vancomycin-resistant S. aureus (VRSA) are defined by bacterial inhibition at doses of <4 mg/mL, 4–8 mg/mL, and ≥16 mg/mL, respectively.Citation113,Citation114 While VRSA has remained very rare, VISA is on the rise in the US.Citation115,Citation116 High-level resistance to vancomycin in VRSA is due to the acquisition of the vanA gene,Citation117 while intermediate resistance is multifactorial and due to genetic alterations that increase the thickness of the cell wall.Citation118

Apart from vancomycin, linezolid, daptomycin, and tigecycline are FDA-approved and effective against MRSA infections.Citation100,Citation119 Notably, daptomycin is ineffective against pulmonary infections.Citation120 In addition, improved β-lactams such as cephalosporins (ceftaroline/ceftobiprole), carbapenems, long-acting tetracyclines (doxycyclines/minocyclines), clindamycin, rifampin, and improved glycopeptides (telavancin) are used to treat mild-to-severe MRSA infections, either alone or in combination therapies.Citation121Citation123

The therapy to be used against an MRSA infection is often determined by the nature and severity of the infection. In cases of mild CA-MSRA skin infections, inexpensive oral agents are recommended. Clindamycin and doxycycline are good choices in this regard,Citation124,Citation125 and are recommended in children with mild CA-MRSA-associated SSTI infections.Citation126 For less severe bacteremia or endocarditis, vancomycin together with a semisynthetic penicillin is the treatment of choice. When the infecting isolate shows a resistance level to vancomycin of .1 mg/mL or in cases of renal failure, daptomycin or linezolid are recommended. Linezolid is particularly favorable in cases of ventilator-associated and hospital-associated pneumonia.Citation127 The IDSA set forward clear guidelines for the treatment of MRSA infections. Vancomycin/daptomycin is the preferred drug for bacteremia and endocarditis, vancomycin/daptomycin along with rifampin for prosthetic valve infections, and vancomycin/linezolid/clindamycin for HA/CA-MRSA pneumonia.

The drugs currently used to treat MRSA infections are progressively showing decreasing efficacy due to increasing bacterial resistance. Several cases of S. aureus resistance to “last-resort drugs,” such as vancomycin, daptomycin, and linezolid, have been reported,Citation128Citation131 which calls for the development of new and improved anti-MRSA drugs. Several new drugs are under development, such as carbapenems (cefonicid, ceftazidime), quinolones, and glycopeptides (dalbavancin, oritavancin).Citation132 Unfortunately, vaccine-intervention strategies against S. aureus have failed so far. An alternative vaccine approach targeting virulence determinants has gained momentum in recent times. Staphylococcal α-toxin, Panton–Valentine leukocidin (PVL), leukocidin ED, and the recently described phenol-soluble modulin (PSM) transporter could serve as potential targets for such an approach (see below).

MRSA typing

There has been a persistent effort to understand the epidemiology of S. aureus by typing the infective isolates, for which a number of molecular methods are currently in practice.Citation12,Citation133 While all methods provide valuable information regarding staphylococcal phylogeny, some are predominantly directed to decipher bacterial microevolution, such as multilocus sequence typing (MLST) and staphylococcal protein A (spa) gene typing, whereas others, such as pulsed-field gel electrophoresis (PFGE) and SCCmec typing, yield more information about large genetic changes, such as gene deletions or duplications.

MLST is based on the sequence analysis of 450-base-pair internal fragments of seven housekeeping genes. Isolates showing sequence similarity in all seven genes are given a unique ST number, and closely related STs are grouped together in a single clonal complex (CC). Spa typing is based on the sequencing of the polymorphic X region of the spa gene.Citation134 Both MLST and spa typing are currently centralized and automated (for MLST, http://saureus.mlst.net; for spa typing, http://www.egenomics.com or http://spaserver.ridom.de).

PFGE is the analysis of DNA fragments following SmaI digestion of the bacterial genome on an agarose gel. PFGE is highly reliable and a gold standard for strain designations.Citation135 However, low portability of data along with regional description of PGFE patterns (in the US, USA100 or USA200 etc; in Australia, WMRSA; in the UK, EMRSA; and in Canada, CMRSA) make it difficult to compare isolates.

SCCmec is an MGE of 21–67 kb in length that contains the mecA gene. Currently, there are eleven different allotypes of SCCmec – types I–XI (http://www.sccmec.org) among S. aureus strains – of which SCCmec type III is the largest and SCCmec type IV the smallest. Due to its smaller size, SCCmec IV is thought to give a fitness advantage compared to other SCCmec types.Citation136,Citation137. Usually HA-MRSA isolates carry SCCmec types I, II, or III, whereas CA-MRSA isolates possess SCCmec types IV, V, or VII.Citation138

Epidemiology of MRSA epidemic waves

S. aureus infection rates rise and fall in epidemic waves. Epidemic waves are rapid and widespread outbursts of S. aureus infections affecting many individuals in an area or population. The causes underlying the appearance and disappearance of S. aureus epidemics are largely unknown, but likely comprise exposure to a new antibacterial agent, or in some cases lifestyle habits.Citation2

Epidemic wave 1 (1950s, phage type 80/81, penicillin-resistant strains)

This first recorded outbreak was caused by penicillin-resistant strains of the phage type 80/81 lineage, following the introduction of penicillin in the 1940s. It started in the UK, and in the 1950s had become a worldwide problem.Citation139

Epidemic wave 2 (1960s, archaic MRSA)

This outbreak was due to the spread of the first MRSA clones, shortly following the introduction of methicillin. It caused mostly serious health-care-associated infections, but also occasionally mild community-associated infections throughout Europe.Citation11

Epidemic wave 3 (1980s, toxic-shock syndrome clones)

Toxic-shock syndrome (TSS), also referred to as staphylococcal scarlet fever, was first reported in 1978 among young menstrual women.Citation140 The following years saw a severe outbreak of TSS cases, with the use of superabsorbent tampons soon discovered to be the underlying risk factor.Citation141 The exotoxin encoded by the tst gene was identified as the single molecular determinant of TSS.Citation142

Epidemic wave 4 (1980s until present, HA-MRSA)

This outbreak followed the rise of a novel MRSA lineage, called Iberian or Rome clone, which became pandemic in the hospitals. Several other strains of S. aureus, such as USA100, USA200, EMRSA-15, and EMRSA-16, emerged as further common HA-MRSA strains and continue to cause a high number of nosocomial infections worldwide.Citation2,Citation143,Citation144

Epidemic wave 5 (1990s until present, CA-MRSA)

This epidemic started in Western Australia with the discovery of the first case of CA-MRSA caused by the WA-1 or WA-MRSA1 strain. A close relative of the WA-1 strain, the USA400 strain, soon became widespread in the US and Canada.Citation19,Citation145 This epidemic wave constitutes two overlapping waves, the first of which was prevalent until 2001 and caused by the USA400 strain. This was followed by the current CA-MRSA pandemic caused by the USA300 strain. Currently, USA300 is the major cause of CA-MRSA infections in many countries, including the US,Citation146 while infections due to USA400 strains are restricted mainly to Alaska and the Pacific Northwest.Citation2

Epidemic wave 6 (early 2000s LA-MRSA outbreak)

This outbreak in humans is caused by a pig-associated MRSA isolate of the CC398 lineage. LA-MRSA was first reported in Europe, but is currently pandemic and can sometimes cause serious infections among healthy livestock workers and veterinarians. The LA-MRSA pandemic exemplifies a rare but increasingly occurring case of shared infection between animals and humans.Citation29,Citation30

Worldwide emergence of epidemic MRSA strains

The majority of MRSA infections are caused by strains belonging to a few CCs. The most prevalent are CC1 (USA400), CC5 (USA100 or NY/Japan clone, USA800 or pediatric clone), CC8 (Col, Iberian clone, USA300, and USA500), CC22 (EMRSA-15), CC30 (USA200, EMRSA-16, USA1100, the Southwest Pacific Oceania clone), CC45 (USA600, Berlin clone), CC59 (Taiwan), and CC80 (Europe).Citation2,Citation133 Of these, CCs 1, 5, 8, 22, 30, and 45 are prominent in the hospitals, whereas CCs 1, 8, 22, 30, 59, and 80 are mostly prevalent in the community. MRSA strains representing CCs 8 and 30 are pandemic both in the hospitals and in the community, and are among the most frequently isolated strains from infections. CC 22 and 30 represented by ST22 (EMRSA-15) and ST36 (EMRSA-16) strains are prevalent in the UK. All known VISA strains belong to CC5. The archaic and Iberian MRSA, USA400, and USA300 strains belong to CC8. Of note, these representative CCs are not exclusive to MRSA, but also include MSSA strains. For example, the phage type 80/81strains discussed above belong to CC30. Finally, there are some regional clones, such as ST772 (Bengal Bay clone), which is mostly prevalent in Bangladesh and India,Citation147 ST72 strains in South Korea, the Caribbean, and Portugal, and ST88 strains in Africa and Asia.Citation133,Citation148,Citation149

Emergence and dominance of USA300 in current CA- and HA-MRSA infections

USA300 has emerged as the dominant CA-MRSA strain in the US.Citation31 First isolated in 2000, it was traditionally a community-associated strain,Citation150 but it now also represents a major threat to patients in hospitals and long-term care facilities.Citation32,Citation151 Additionally, USA300 is increasingly responsible for the majority of CA-MRSA infections worldwide, including in Canada, Europe, Australia, Japan, and Latin America.Citation146,Citation152Citation154

Consistent with USA300’s global dominance, laboratory experiments show elevated virulence of this strain compared to contemporary MRSA isolates.Citation155,Citation156 Notably, the USA300 strains in the US are highly clonal and closely genetically related.Citation157 While the evolution of CA-MRSA virulence, and in particular that of USA300, is a matter of ongoing debate,Citation18 the enormous success of USA300 is attributed generally to increased resistance of USA300 to antimicrobial agents,Citation67,Citation158,Citation159 increased expression of virulence genesCitation156 and their regulators, higher persistence,Citation25 and acquisition of virulence determinants on MGEs, such as PVLCitation160 (see below).

Recent emergence of LA-MRSA

The first case of LA-MRSA was reported in 1972 in cows.Citation41 LA-MRSA is associated with a relatively small number of lineages. For example, bovine infections are caused predominantly by strains belonging to CC97, CC126, CC130, and ST151. CC398 and ST9 are predominantly present in pigs. The isolation of a novel mecA gene (mecALGA251), also known as me,Citation161 from cattle suggests that LA-MRSA strains are distinct from HA- and CA-MRSA. Recently, bovine-specific LA-MRSA strains were isolated from humans in the UK, Denmark, and Germany,Citation162 suggesting that cows can serve as a reservoir for human MRSA. Subsequently, several cases of LA-MRSA-mediated human infections were reported throughout the world. The underlying risk factor for these infections is primarily exposure to livestock.Citation40

CC398 was first discovered in Europe in early 2000 and rapidly became the major cause of human LA-MRSA infections. Studies performed in Denmark and Belgium showed that livestock-associated veterinarians have a high chance of being infected by CC398 LA-MRSA strains.Citation163 Presently, CC398-mediated LA-MRSA infections have reached pandemic proportions, as several cases have been reported from such geographically diverse locations as Canada, China, Colombia, and the Caribbean.Citation148,Citation164,Citation165 In the Netherlands, human cases of CC398 infections represent 25% of total MRSA infections.Citation166 Pigs are thought to be the major asymptomatic carriers of CC398 clonesCitation167; however, CC398 strains have also occurred in cows, veal, poultry, horses, and dogs.Citation46 CC398 clones show high diversity.Citation168 Interestingly, cases of CC398 MSSA strains colonizing healthy individuals have been reported in the US.Citation169 Recent research indicates that the CC398 LA-MRSA strains may have been derived from a human MSSA CC398 isolate that was transferred to pigs, where it obtained the SCCmec cluster.Citation168

Evolution of MRSA pathogenic success

The success of S. aureus as a pathogen is to a large extent due to its ability to resist antimicrobial agents and circumvent the immune surveillance of the host. Many molecular determinants of resistance and virulence in S. aureus are encoded on MGEs. The presence of those factors is thus highly strain-dependent, while some core genome-encoded virulence determinants are present in virtually all strains.

The commonly MGE-encoded determinants of antimicrobial resistance have already been discussed in previous sections. In addition, S. aureus possesses an enormous repertoire of virulence and persistence genes that may be genome- or MGE-encoded. In this article, only a selected few are presented. The reader is referred to review articles presenting the molecular basis of S. aureus virulence in more detail.Citation18,Citation170

The core genome-encoded pore-forming toxin, a-toxin, is produced by most S. aureus strains. a-Toxin is proinflammatory, shows cytolytic effects to various immune cells except human neutrophils,Citation171 and is critical for S. aureus virulence in various animal models of infection.Citation172,Citation173 Vaccination with a nontoxic a-toxin variant provides protection against staphylococcal pneumonia and skin infection.Citation174,Citation175

PSMs are a group of small, core genome-encoded amphipathic peptides of~20–45 amino acids. They are present in all S. aureus strains and considered key determinants in the development of skin, bloodstream, and biofilm-associated infections.Citation176,Citation177 In particular a-type PSMs are strongly cytolytic toward neutrophils and erythrocytes at the micromolar range.Citation176 Notably, PSMa peptides of S. aureus destroy neutrophils after phagocytosis from within the neutrophil phagosome.Citation178,Citation179 At nanomolar concentrations, all PSMs are proinflammatory by receptor-mediated interaction.Citation176,Citation180 The PSM-secretion machinery in S. aureus has recently been identifiedCitation179 potentially representing a target for simultaneous interference with all PSMs.

Leukotoxins are perhaps the most extensively studied staphylococcal virulence determinants in recent times. Clinical strains of S. aureus may produce four different types of bicomponent leukotoxins, namely PVL, γ-hemolysin, leukotoxin ED, and/or leukotoxin AB/GH.Citation181 Apart from γ-hemolysin, they are all MGE-encoded.Citation182 All leukotoxins are proinflammatory and show cytolytic activity towards neutrophils, with considerable host specificityCitation183Citation186 Recently, the CCR5 receptor was shown to recognize leukotoxin ED,Citation187 suggesting that in contrast to previous belief, the cytolytic activities of – possibly all – staphylococcal leukotoxins are receptor-dependent.

ACME harbors a set of genes that enable the bacteria to utilize arginine present on human skin to their metabolic advantage and detoxify host-derived antimicrobial agents.Citation24,Citation25 Of note, ACME, likely acquired from S. epidermidis, is exclusively present in the USA300 background among S. aureus strains, potentially explaining the superiority of USA300 over other CA-MRSA strains.

Current efforts in understanding molecular MRSA epidemiology

There has been a recent emphasis on understanding MRSA epidemic waves on the molecular level. In a rare effort to combine epidemiological and functional analyses for that purpose, an S. aureus MGE-encoded factor, the surface protein SasX, was identified to be significantly increasing in frequency among Asian HA-MRSA strains. Notably, SasX was found to be associated with increased nasal colonization, immune evasion and virulence.Citation188 Furthermore, genome comparison of the pandemic phage type 80/81 strain with that of a contemporary CC30 HA-MRSA strain showed that a truncated α-toxin gene and mutated agrC led to a reduction in aggressive virulence in the contemporary HA-MRSA CC30 background, possibly explaining the success of those clones in the hospital environment.Citation189 Further genome-wide studies were recently performed to document the evolution of bacterial resistance to vancomycin and linezolid within patients during antimicrobial therapy.Citation190Citation193 Several longitudinal studies with isolates from cystic fibrosis,Citation194 persistent infections in households,Citation195 and an MRSA clone before and after BSICitation196 revealed several subtle genetic changes compromising virulence, cell-wall biosynthesis, and antimicrobial resistance. All these studies suggest that minor genetic adaptations may contribute to the development of MRSA fitness and persistence.

Current surveillance efforts

Active surveillance of MRSA with guidelines for proper treatment and documentation of hospital-associated MRSA cases is performed in many countries. The so-called search-and-destroy approach to deal with MRSA cases is practiced in many parts of Europe, including the Scandinavian countries and the Netherlands. It involves the routine screening of patients and health-care personnel for MRSA, and has proved to be highly successful.Citation197,Citation198 Because poor hygiene correlates with a higher prevalence of MRSA, and improper use of antibiotics with a higher MRSA carriage,Citation199 the control of MRSA includes cost-effective sanitizing methods, such as proper hand-washing and an overall restrained use of antibiotics. Recent clinical data show that HA-MRSA cases have been on a decline in the US between 2005 and 2008Citation200 and in the UK since 2006, probably due at least in part to these measures, and in the latter case the mandatory surveillance of MRSA.Citation201,Citation202

Concluding remarks

Half a century after its surge, MRSA remains a serious threat to public health-care systems worldwide. MRSA strains have gained resistance to a variety of antibiotics, and an S. aureus vaccine is not available or in sight. Owing to the low fitness cost associated with methicillin resistance and the relatively easy transmission from infected individuals or fomites, the bacteria can spread easily. The surge in global travel over the last few decades has added to the spread of MRSA. It is now a generally accepted view that proper management of the MRSA problem needs a multipronged approach. This approach should include global surveillance of MRSA, development of new and improved antimicrobial agents, and increased understanding of MRSA pathophysiology through basic scientific research.

Acknowledgments

This work was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases (NIAID), US National Institutes of Health (NIH).

Disclosure

The authors report no conflicts of interest in this work.

References

  • MishraRPOviedo-OrtaEPrachiPRappuoliRBagnoliFVaccines and antibiotic resistanceCurr Opin Microbiol20121559660222981392
  • ChambersHFDeLeoFRWaves of resistance: Staphylococcus aureus in the antibiotic eraNat Rev Microbiol2009762964119680247
  • MoelleringRCJrPast, present, and future of antimicrobial agentsAm J Med19959911S18S8585528
  • LowyFDStaphylococcus aureus infectionsN Engl J Med19983395205329709046
  • KirbyHUne faute de transcription, d’orthographe, ou d’impressionScience194410042542717830677
  • DemerecMProduction of Staphylococcus strains resistant to various concentrations of penicillinProc Natl Acad Sci USA194531162416588677
  • MurrayBEMoelleringRCJrPatterns and mechanisms of antibiotic resistanceMed Clin North Am197862899923366296
  • AbrahamEPChainEAn enzyme from bacteria able to destroy penicillin. 1940Rev Infect Dis1988106776783055168
  • RountreePMFreemanBMBarbourRGNasal carriage of Staphylococcus aureus in the general population and its relationship to hospitalization and to penicillin therapyMed J Aust1954245746013213371
  • JevonsMPParkerMTThe evolution of new hospital strains of Staphylococcus aureusJ Clin Pathol19641724325014159451
  • JevonsMPRolinsonGNKnoxRCelbenin-resistant staphylococciBMJ19611124126
  • MatsuhashiMSongMDIshinoFMolecular cloning of the gene of a penicillin-binding protein supposed to cause high resistance to beta-lactam antibiotics in Staphylococcus aureusJ Bacteriol19861679759803638304
  • MurakamiKTomaszAInvolvement of multiple genetic determinants in high-level methicillin resistance in Staphylococcus aureusJ Bacteriol19891718748792536684
  • ItoTKatayamaYHiramatsuKCloning and nucleotide sequence determination of the entire mec DNA of pre-methicillin-resistant Staphylococcus aureus N315Antimicrob Agents Chemother1999431449145810348769
  • CharleboisEDPerdreau-RemingtonFKreiswirthBOrigins of community strains of methicillin-resistant Staphylococcus aureusClin Infect Dis200439475415206052
  • DeLeoFROttoMKreiswirthBNChambersHFCommunity-associated meticillin-resistant Staphylococcus aureusLancet20103751557156820206987
  • DeLeoFRChambersHFReemergence of antibiotic-resistant Staphylococcus aureus in the genomics eraJ Clin Invest20091192464247419729844
  • OttoMBasis of virulence in community-associated methicillin-resistant Staphylococcus aureusAnnu Rev Microbiol20106414316220825344
  • UdoEEPearmanJWGrubbWBGenetic analysis of community isolates of methicillin-resistant Staphylococcus aureus in Western AustraliaJ Hosp Infect199325971087903093
  • [No authors listed]From the Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus – Minnesota and North Dakota, 1997–1999JAMA19992821123112510501104
  • HeroldBCImmergluckLCMarananMCCommunity-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing riskJAMA19982795935989486753
  • VandeneschFNaimiTEnrightMCCommunity-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergenceEmerg Infect Dis2003997898412967497
  • OttoMMRSA virulence and spreadCell Microbiol2012141513152122747834
  • JoshiGSSpontakJSKlapperDGRichardsonARArginine catabolic mobile element encoded speG abrogates the unique hypersensitivity of Staphylococcus aureus to exogenous polyaminesMol Microbiol20118292021902734
  • ThurlowLRJoshiGSClarkJRFunctional modularity of the arginine catabolic mobile element contributes to the success of USA300 methicillin-resistant Staphylococcus aureusCell Host Microbe20131310010723332159
  • SkovRChristiansenKDancerSJUpdate on the prevention and control of community-acquired meticillin-resistant Staphylococcus aureus (CA-MRSA)Int J Antimicrob Agents20123919320022226649
  • ScanvicADenicLGaillonSGiryPAndremontALucetJCDuration of colonization by methicillin-resistant Staphylococcus aureus after hospital discharge and risk factors for prolonged carriageClin Infect Dis2001321393139811317238
  • KlevensRMMorrisonMAFridkinSKCommunity-associated methicillin-resistant Staphylococcus aureus and healthcare risk factorsEmerg Infect Dis2006121991199317326962
  • OtterJAFrenchGLCommunity-associated meticillin-resistant Staphylococcus aureus: the case for a genotypic definitionJ Hosp Infect20128114314822622448
  • JimenezJNOcampoAMVanegasJMCC8 MRSA strains harboring SCCmec type IVc are predominant in Colombian hospitalsPLoS One20127e3857622745670
  • TattevinPDiepBAJulaMPerdreau-RemingtonFLong-term follow-up of methicillin-resistant Staphylococcus aureus molecular epidemiology after emergence of clone USA300 in San Francisco jail populationsJ Clin Microbiol2008464056405718923004
  • TattevinPDiepBAJulaMPerdreau-RemingtonFMethicillin-resistant Staphylococcus aureus USA300 clone in long-term care facilityEmerg Infect Dis20091595395519523301
  • TenoverFCTicklerIAGoeringRVKreiswirthBNMediavillaJRPersingDHCharacterization of nasal and blood culture isolates of methicillin-resistant Staphylococcus aureus from patients in United States HospitalsAntimicrob Agents Chemother2012561324133022155818
  • Abdel-HaqNAl-TatariHChearskulPMethicillin-resistant Staphylococcus aureus (MRSA) in hospitalized children: correlation of molecular analysis with clinical presentation and antibiotic susceptibility testing (ABST) resultsEur J Clin Microbiol Infect Dis20092854755119020911
  • BradleyABovine mastitis: an evolving diseaseVet J200216411612812359466
  • MenziesPIRamanoonSZMastitis of sheep and goatsVet Clin North Am Food Anim Pract200117333358vii11515405
  • McNameePTSmythJABacterial chondronecrosis with osteomyelitis (‘femoral head necrosis’) of broiler chickens: a reviewAvian Pathol20002947749519184841
  • VancraeynestDHaesebrouckFDeplanoAInternational dissemination of a high virulence rabbit Staphylococcus aureus cloneJ Vet Med B Infect Dis Vet Public Health20065341842217062118
  • CunyCFriedrichAKozytskaSEmergence of methicillin-resistant Staphylococcus aureus (MRSA) in different animal speciesInt J Med Microbiol201030010911720005777
  • Armand-LefevreLRuimyRAndremontAClonal comparison of Staphylococcus aureus isolates from healthy pig farmers, human controls, and pigsEmerg Infect Dis20051171171415890125
  • DevrieseLAVan DammeLRFamereeLMethicillin (cloxacillin)-resistant Staphylococcus aureus strains isolated from bovine mastitis casesZentralbl Veterinarmed B1972195986054486473
  • LowderBVGuinaneCMBen ZakourNLRecent human-to-poultry host jump, adaptation, and pandemic spread of Staphylococcus aureusProc Natl Acad Sci USA2009106195451955019884497
  • MusserJMSchlievertPMChowAWA single clone of Staphylococcus aureus causes the majority of cases of toxic shock syndromeProc Natl Acad Sci USA1990872252291967495
  • DevrieseLAA simplified system for biotyping Staphylococcus aureus strains isolated from animal speciesJ Appl Bacteriol1984562152206373707
  • KloosWENatural populations of the genus StaphylococcusAnnu Rev Microbiol1980345595927002032
  • FluitACLivestock-associated Staphylococcus aureusClin Microbiol Infect20121873574422512702
  • WaltherBWielerLHVinczeSMRSA variant in companion animalsEmerg Infect Dis2012182017202023171478
  • PetinakiESpiliopoulouIMethicillin-resistant Staphylococcus aureus among companion and food-chain animals: impact of human contactsClin Microbiol Infect20121862663422550956
  • MorrisDOLautenbachEZaoutisTLeckermanKEdelsteinPHRankinSCPotential for pet animals to harbour methicillin-resistant Staphylococcus aureus when residing with human MRSA patientsZoonoses Public Health20125928629322233337
  • FairesMCTaterKCWeeseJSAn investigation of methicillin-resistant Staphylococcus aureus colonization in people and pets in the same household with an infected person or infected petJ Am Vet Med Assoc200923554054319719444
  • CoughlanKOlsenKEBoxrudDBenderJBMethicillin-resistant Staphylococcus aureus in resident animals of a long-term care facilityZoonoses Public Health20105722022620042067
  • HaenniMChatrePBoissetSStaphylococcal nasal carriage in calves: multiresistant Staphylococcus sciuri and immune evasion cluster (IEC) genes in methicillin-resistant Staphylococcus aureus ST398J Antimicrob Chemother2011661927192821609981
  • LinYBarkerEKislowJEvidence of multiple virulence subtypes in nosocomial and community-associated MRSA genotypes in companion animals from the upper midwestern and northeastern United StatesClin Med Res2011971620739580
  • GrahamPL3rdLinSXLarsonELA US population-based survey of Staphylococcus aureus colonizationAnn Intern Med200614431832516520472
  • von EiffCBeckerKMachkaKStammerHPetersGNasal carriage as a source of Staphylococcus aureus bacteremia. Study GroupN Engl J Med2001344111611136954
  • Schechter-PerkinsEMMitchellPMMurrayKARubin-SmithJEWeirSGuptaKPrevalence and predictors of nasal and extranasal staphylococcal colonization in patients presenting to the emergency departmentAnn Emerg Med20115749249921239081
  • GorwitzRJKruszon-MoranDMcAllisterSKChanges in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001–2004J Infect Dis20081971226123418422434
  • TenoverFCMcAllisterSFosheimGCharacterization of Staphylococcus aureus isolates from nasal cultures collected from individuals in the United States in 2001 to 2004J Clin Microbiol2008462837284118632911
  • CreechCB2ndKernodleDSAlsentzerAWilsonCEdwardsKMIncreasing rates of nasal carriage of methicillin-resistant Staphylococcus aureus in healthy childrenPediatr Infect Dis J20052461762115999003
  • WenzelRPPerlTMThe significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infectionJ Hosp Infect19953113247499817
  • MillerLGDiepBAClinical practice: colonization, fomites, and virulence: rethinking the pathogenesis of community-associated methicillin-resistant Staphylococcus aureus infectionClin Infect Dis20084675276018220477
  • KazakovaSVHagemanJCMatavaMA clone of methicillin-resistant Staphylococcus aureus among professional football playersN Engl J Med200535246847515689585
  • Elie-TurenneMCFernandesHMediavillaJRPrevalence and characteristics of Staphylococcus aureus colonization among healthcare professionals in an urban teaching hospitalInfect Control Hosp Epidemiol20103157458020426580
  • JarvisWRSchlosserJChinnRYTweetenSJacksonMNational prevalence of methicillin-resistant Staphylococcus aureus in inpatients at US health care facilities, 2006Am J Infect Control20073563163718063126
  • FitzgeraldJRLivestock-associated Staphylococcus aureus: origin, evolution and public health threatTrends Microbiol20122019219822386364
  • AielloAELowyFDWrightLNLarsonELMeticillin-resistant Staphylococcus aureus among US prisoners and military personnel: review and recommendations for future studiesLancet Infect Dis2006633534116728319
  • DiepBAChambersHFGraberCJEmergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with menAnn Intern Med200814824925718283202
  • AdcockPMPastorPMedleyFPattersonJEMurphyTVMethicillin-resistant Staphylococcus aureus in two child care centersJ Infect Dis19981785775809697748
  • KluytmansJAMoutonJWIjzermanEPNasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgeryJ Infect Dis19951712162197798667
  • TuazonCUPerezAKishabaTSheagrenJNStaphylococcus aureus among insulin-injecting diabetic patients. An increased carrier rateJAMA197523112721172956
  • DinauerMCChronic granulomatous disease and other disorders of phagocyte functionHematology Am Soc Hematol Educ Program2005899516304364
  • ShadyabAHCrum-CianfoneNFMethicillin-resistant Staphylococcus aureus (MRSA) infections among HIV-infected persons in the era of highly active antiretroviral therapy: a review of the literatureHIV Med20121331933222276696
  • OlsenRJBurnsKMChenLKreiswirthBNMusserJMSevere necrotizing fasciitis in a human immunodeficiency virus-positive patient caused by methicillin-resistant Staphylococcus aureusJ Clin Microbiol2008461144114718199782
  • FridkinSKHagemanJCMorrisonMMethicillin-resistant Staphylococcus aureus disease in three communitiesN Engl J Med20053521436144415814879
  • TrillaAMiroJMIdentifying high risk patients for Staphylococcus aureus infections: skin and soft tissue infectionsJ Chemother19957 Suppl 337438609537
  • ArnoldSREliasDBuckinghamSCChanging patterns of acute hematogenous osteomyelitis and septic arthritis: emergence of community-associated methicillin-resistant Staphylococcus aureusJ Pediatr Orthop20062670370817065930
  • FrancisJSDohertyMCLopatinUSevere community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genesClin Infect Dis20054010010715614698
  • BassettiMTrecarichiEMMesiniARisk factors and mortality of healthcare-associated and community-acquired Staphylococcus aureus bacteraemiaClin Microbiol Infect20121886286921999245
  • TownellNJMunckhofWJNimmoGCommunity-associated methicillin-resistant Staphylococcus aureus endocarditis ‘down under’: case series and literature reviewScand J Infect Dis20124453654022404422
  • TattevinPSchwartzBSGraberCJConcurrent epidemics of skin and soft tissue infection and bloodstream infection due to community-associated methicillin-resistant Staphylococcus aureusClin Infect Dis20125578178822670044
  • ShorrAFTabakYPKillianADGuptaVLiuLZKollefMHHealthcare-associated bloodstream infection: a distinct entity? Insights from a large US databaseCrit Care Med2006342588259516915117
  • AsaiTHikiMBabaKUsuiMIshiharaKTamuraYPresence of Staphylococcus aureus ST398 and ST9 in swine in JapanJpn J Infect Dis20126555155223183212
  • KlevensRMEdwardsJRTenoverFCMcDonaldLCHoranTGaynesRChanges in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992–2003Clin Infect Dis20064238939116392087
  • KleinESmithDLLaxminarayanRHospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999–2005Emerg Infect Dis2007131840184618258033
  • ChambersHFThe changing epidemiology of Staphylococcus aureus?Emerg Infect Dis2001717818211294701
  • GouldIMReillyJBunyanDWalkerACosts of healthcare-associated methicillin-resistant Staphylococcus aureus and its controlClin Microbiol Infect2010161721172820825434
  • KlevensRMMorrisonMANadleJInvasive methicillin-resistant Staphylococcus aureus infections in the United StatesJAMA20072981763177117940231
  • HanbergerHWaltherSLeoneMIncreased mortality associated with methicillin-resistant Staphylococcus aureus (MRSA) infection in the intensive care unit: results from the EPIC II studyInt J Antimicrob Agents20113833133521798720
  • ThwaitesGEThe management of Staphylococcus aureus bacteremia in the United Kingdom and Vietnam: a multi-centre evaluationPLoS One20105e1417021179193
  • FiliceGANymanJALexauCExcess costs and utilization associated with methicillin resistance for patients with Staphylococcus aureus infectionInfect Control Hosp Epidemiol20103136537320184420
  • CurtisLTPrevention of hospital-acquired infections: review of non-pharmacological interventionsJ Hosp Infect20086920421918513830
  • CosgroveSEQiYKayeKSHarbarthSKarchmerAWCarmeliYThe impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital chargesInfect Control Hosp Epidemiol20052616617415756888
  • ClancyMGraeplerAWilsonMDouglasIJohnsonJPriceCSActive screening in high-risk units is an effective and cost-avoidant method to reduce the rate of methicillin-resistant Staphylococcus aureus infection in the hospitalInfect Control Hosp Epidemiol2006271009101717006806
  • Saavedra-LozanoJMejiasAAhmadNChanging trends in acute osteomyelitis in children: impact of methicillin-resistant Staphylococcus aureus infectionsJ Pediatr Orthop20082856957518580375
  • MurilloJLCohenMKreiswirthBResults of nasal screening for methicillin-resistant Staphylococcus aureus during a neonatal intensive care unit outbreakAm J Perinatol201027798119544247
  • MylotteJMMcDermottCStaphylococcus aureus bacteremia caused by infected intravenous cathetersAm J Infect Control198715163645972
  • MoelleringRCJrThe growing menace of community-acquired methicillin-resistant Staphylococcus aureusAnn Intern Med200614436837016520479
  • MoranGJKrishnadasanAGorwitzRJMethicillin-resistant S. aureus infections among patients in the emergency departmentN Engl J Med200635566667416914702
  • YuVLGoetzAWagenerMStaphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxisN Engl J Med198631591963523240
  • StryjewskiMEChambersHFSkin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureusClin Infect Dis200846 Suppl 5S368S37718462092
  • TenoverFCMcDougalLKGoeringRVCharacterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United StatesJ Clin Microbiol20064410811816390957
  • GraberCJJacobsonMAPerdreau-RemingtonFChambersHFDiepBARecurrence of skin and soft tissue infection caused by methicillin-resistant Staphylococcus aureus in a HIV primary care clinicJ Acquir Immune Defic Syndr20084923123318820536
  • JensenAGWachmannCHEspersenFScheibelJSkinhøjPFrimodt-MøllerNTreatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 casesArch Intern Med2002162253211784216
  • JohnsonLBAlmoujahedMOIlgKMaoloodLKhatiRStaphylococcus aureus bacteremia: compliance with standard treatment, long-term outcome and predictors of relapseScand J Infect Dis20033578278914723349
  • FowlerVGJrSandersLLSextonDJOutcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patientsClin Infect Dis1998274784869770144
  • LiuCBayerACosgroveSEClinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summaryClin Infect Dis20115228529221217178
  • HershALChambersHFMaselliJHGonzalesRNational trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infectionsArch Intern Med20081681585159118663172
  • LevineDPFrommBSReddyBRSlow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditisAnn Intern Med19911156746801929035
  • Siegman-IgraYReichPOrni-WasserlaufRSchwartzDGiladiMThe role of vancomycin in the persistence or recurrence of Staphylococcus aureus bacteraemiaScand J Infect Dis20053757257816138425
  • KhatibRJohnsonLBFakihMGPersistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcomeScand J Infect Dis20063871416338832
  • FalagasMEMantaKGNtzioraFVardakasKZLinezolid for the treatment of patients with endocarditis: a systematic review of the published evidenceJ Antimicrob Chemother20065827328016735427
  • ThwaitesGEEdgeworthJDGkrania-KlotsasEClinical management of Staphylococcus aureus bacteraemiaLancet Infect Dis20111120822221371655
  • HiramatsuKAritakaNHanakiHDissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycinLancet1997350167016739400512
  • WeigelLMClewellDBGillSRGenetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureusScience20033021569157114645850
  • RybakMJLeonardSNRossiKLCheungCMSaderHSJonesRNCharacterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007)J Clin Microbiol2008462950295418632899
  • BaeIGFederspielJJMiroJMHeterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significanceJ Infect Dis20092001355136619811099
  • AppelbaumPCReduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA)Int J Antimicrob Agents20073039840817888634
  • HiramatsuKCuiLKurodaMItoTThe emergence and evolution of methicillin-resistant Staphylococcus aureusTrends Microbiol2001948649311597450
  • GouldIMClinical activity of anti-Gram-positive agents against methicillin-resistant Staphylococcus aureusJ Antimicrob Chemother201166Suppl 4iv17iv2121521703
  • PertelPEBernardoPFogartyCEffects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumoniaClin Infect Dis2008461142115118444848
  • MillerMHWexlerMASteigbigelNHSingle and combination antibiotic therapy of Staphylococcus aureus experimental endocarditis: emergence of gentamicin-resistant mutantsAntimicrob Agents Chemother197814336343251069
  • WilsonWRKarchmerAWDajaniASAntibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart AssociationJAMA1995274170617137474277
  • DworkinRJLeeBLSandeMAChambersHFTreatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicinLancet19892107110732572799
  • BraunLCraftDWilliamsRTuamokumoFOttoliniMIncreasing clindamycin resistance among methicillin-resistant Staphylococcus aureus in 57 northeast United States military treatment facilitiesPediatr Infect Dis J20052462262615999004
  • RuheJJMenonATetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureusAntimicrob Agents Chemother2007513298330317576834
  • FrankALMarcinakJFMangatPDClindamycin treatment of methicillin-resistant Staphylococcus aureus infections in childrenPediatr Infect Dis J20022153053412182377
  • GouldIMCaudaREspositoSGudiolFMazzeiTGarauJManagement of serious meticillin-resistant Staphylococcus aureus infections: what are the limits?Int J Antimicrob Agents20113720220921300528
  • CuiLIsiiTFukudaMAn RpoB mutation confers dual heter-oresistance to daptomycin and vancomycin in Staphylococcus aureusAntimicrob Agents Chemother2010545222523320837752
  • FriedmanLAlderJDSilvermanJAGenetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureusAntimicrob Agents Chemother2006502137214516723576
  • YangSJKreiswirthBNSakoulasGEnhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureusJ Infect Dis20092001916192019919306
  • MoralesGPicazoJJBaosEResistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureusClin Infect Dis20105082182520144045
  • GouldIMDavidMZEspositoSNew insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistanceInt J Antimicrob Agents2012399610422196394
  • MediavillaJRChenLMathemaBKreiswirthBNGlobal epidemiology of community-associated methicillin resistant Staphylococcus aureus (CA-MRSA)Curr Opin Microbiol20121558859523044073
  • FrenayHMBunschotenAESchoulsLMMolecular typing of methicillin-resistant Staphylococcus aureus on the basis of protein A gene polymorphismEur J Clin Microbiol Infect Dis19961560648641305
  • BannermanTLHancockGATenoverFCMillerJMPulsed-field gel electrophoresis as a replacement for bacteriophage typing of Staphylococcus aureusJ Clin Microbiol1995335515557751356
  • LeeSMEnderMAdhikariRFitness cost of staphylococcal cassette chromosome mec in methicillin-resistant Staphylococcus aureus by way of continuous cultureAntimicrob Agents Chemother2007511497149917283194
  • CollinsJRudkinJReckerMPozziCO’GaraJPMasseyRCOffsetting virulence and antibiotic resistance costs by MRSAISME J2010457758420072161
  • DeurenbergRHStobberinghEEThe molecular evolution of hospital-and community-associated methicillin-resistant Staphylococcus aureusCurr Mol Med2009910011519275621
  • BlairJECarrMDistribution of phage groups of Staphylococcus aureus in the years 1927 through 1947Science19601321247124817801672
  • ToddJFishautMKapralFWelchTToxic-shock syndrome associated with phage-group-I staphylococciLancet197821116111882681
  • ShandsKNSchmidGPDanBBToxic-shock syndrome in menstruating women: association with tampon use and Staphylococcus aureus and clinical features in 52 casesN Engl J Med1980303143614427432402
  • SchlievertPMShandsKNDanBBSchmidGPNishimuraRDIdentification and characterization of an exotoxin from Staphylococcus aureus associated with toxic-shock syndromeJ Infect Dis19811435095166972418
  • MatoRCampanileFStefaniSClonal types and multidrug resistance patterns of methicillin-resistant Staphylococcus aureus (MRSA) recovered in Italy during the 1990sMicrob Drug Resist20041010611315256025
  • EnrightMCRobinsonDARandleGFeilEJGrundmannHSprattBGThe evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA)Proc Natl Acad Sci USA2002997687769212032344
  • CoombsGWPearsonJCO’BrienFGMurrayRJGrubbWBChristiansenKJMethicillin-resistant Staphylococcus aureus clones, Western AustraliaEmerg Infect Dis20061224124716494749
  • NimmoGRUSA300 abroad: global spread of a virulent strain of community-associated methicillin-resistant Staphylococcus aureusClin Microbiol Infect20121872573422448902
  • MoneckeSCoombsGShoreACA field guide to pandemic, epidemic and sporadic clones of methicillin-resistant Staphylococcus aureusPLoS One20116e1793621494333
  • UhlemannACDumortierCHaferCMolecular characterization of Staphylococcus aureus from outpatients in the Caribbean reveals the presence of pandemic clonesEur J Clin Microbiol Infect Dis20123150551121789605
  • TavaresDASa-LeaoRMiragaiaMde LencastreHLarge screening of CA-MRSA among Staphylococcus aureus colonizing healthy young children living in two areas (urban and rural) of PortugalBMC Infect Dis20101011020438633
  • PanESDiepBACarletonHAIncreasing prevalence of methicillin-resistant Staphylococcus aureus infection in California jailsClin Infect Dis2003371384138814583874
  • KingMDHumphreyBJWangYFKourbatovaEVRaySMBlumbergHMEmergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infectionsAnn Intern Med200614430931716520471
  • RoloJMiragaiaMTurlej-RogackaAHigh genetic diversity among community-associated Staphylococcus aureus in Europe: results from a multicenter studyPLoS One20127e3476822558099
  • ReyesJRinconSDiazLDissemination of methicillin-resistant Staphylococcus aureus USA300 sequence type 8 lineage in Latin AmericaClin Infect Dis2009491861186719911971
  • NicholKAAdamHJHussainZComparison of community-associated and health care-associated methicillin-resistant Staphylococcus aureus in Canada: results of the CANWARD 2007–2009 studyDiagn Microbiol Infect Dis20116932032521353960
  • MontgomeryCPBoyle-VavraSAdemPVComparison of virulence in community-associated methicillin-resistant Staphylococcus aureus pulsotypes USA300 and USA400 in a rat model of pneumoniaJ Infect Dis200819856157018598194
  • LiMDiepBAVillaruzAEEvolution of virulence in epidemic community-associated methicillin-resistant Staphylococcus aureusProc Natl Acad Sci USA20091065883588819293374
  • KennedyADOttoMBraughtonKREpidemic community-associated methicillin-resistant Staphylococcus aureus: recent clonal expansion and diversificationProc Natl Acad Sci USA20081051327133218216255
  • McDougalLKFosheimGENicholsonAEmergence of resistance among USA300 methicillin-resistant Staphylococcus aureus isolates causing invasive disease in the United StatesAntimicrob Agents Chemother2010543804381120585117
  • CadillaADavidMZDaumRSBoyle-VavraSAssociation of high-level mupirocin resistance and multidrug-resistant methicillin-resistant Staphylococcus aureus at an academic center in the midwestern United StatesJ Clin Microbiol2011499510021084520
  • DiepBAGillSRChangRFComplete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureusLancet200636773173916517273
  • ItoTHiramatsuKTomaszAGuidelines for reporting novel mecA gene homologuesAntimicrob Agents Chemother2012564997499922869575
  • PantostiAMethicillin-resistant Staphylococcus aureus associated with animals and its relevance to human healthFront Microbiol2012312722509176
  • Garcia-GraellsCAntoineJLarsenJCatryBSkovRDenisOLivestock veterinarians at high risk of acquiring methicillin-resistant Staphylococcus aureus ST398Epidemiol Infect201214038338922082716
  • SmithTCPearsonNThe emergence of Staphylococcus aureus ST398Vector Borne Zoonotic Dis20111132733920925523
  • BhatMDumortierCTaylorBSStaphylococcus aureus ST398, New York City and Dominican RepublicEmerg Infect Dis20091528528719193274
  • van CleefBAMonnetDLVossALivestock-associated methicillin-resistant Staphylococcus aureus in humans, EuropeEmerg Infect Dis20111750250521392444
  • MeemkenDBlahaTTegelerRLivestock associated methicillin-resistant Staphylococcus aureus (LaMRSA) isolated from lesions of pigs at necropsy in northwest Germany between 2004 and 2007Zoonoses Public Health201057e143e14820042059
  • PriceLBSteggerMHasmanHStaphylococcus aureus CC398: host adaptation and emergence of methicillin resistance in livestockMBio20123e305e311
  • MediavillaJRChenLUhlemannACMethicillin-susceptible Staphylococcus aureus ST398, New York and New Jersey, USAEmerg Infect Dis20121870070222469250
  • FosterTJImmune evasion by staphylococciNat Rev Microbiol2005394895816322743
  • BartlettAHFosterTJHayashidaAParkPWAlpha-toxin facilitates the generation of CXC chemokine gradients and stimulates neutrophil homing in Staphylococcus aureus pneumoniaJ Infect Dis20081981529153518823272
  • KobayashiSDMalachowaNWhitneyARComparative analysis of USA300 virulence determinants in a rabbit model of skin and soft tissue infectionJ Infect Dis201120493794121849291
  • Bubeck WardenburgJBaeTOttoMDeLeoFRSchneewindOPoring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumoniaNat Med2007131405140618064027
  • Bubeck WardenburgJSchneewindOVaccine protection against Staphylococcus aureus pneumoniaJ Exp Med200820528729418268041
  • KennedyADBubeck WardenburgJGardnerDJTargeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse modelJ Infect Dis20102021050105820726702
  • WangRBraughtonKRKretschmerDIdentification of novel cytolytic peptides as key virulence determinants for community-associated MRSANat Med2007131510151417994102
  • PeriasamySJooHSDuongACHow Staphylococcus aureus biofilms develop their characteristic structureProc Natl Acad Sci USA20121091281128622232686
  • SurewaardBGde HaasCJVervoortFStaphylococcal alpha-phenol soluble modulins contribute to neutrophil lysis after phagocytosisCell Microbiol Epub382013
  • ChatterjeeSSJooHSDuongACEssential Staphylococcus aureus toxin export systemNat Med20131936436723396209
  • KretschmerDGleskeAKRautenbergMHuman formyl peptide receptor 2 senses highly pathogenic Staphylococcus aureusCell Host Microbe2010746347320542250
  • YoongPTorresVJThe effects of Staphylococcus aureus leukotoxins on the host: cell lysis and beyondCurr Opin Microbiol201316636923466211
  • MalachowaNDeLeoFRMobile genetic elements of Staphylococcus aureusCell Mol Life Sci2010673057307120668911
  • LofferBHussainMGrundmeierMStaphylococcus aureus Panton-Valentine leukocidin is a very potent cytotoxic factor for human neutrophilsPLoS Pathog20106e100071520072612
  • DumontALNygaardTKWatkinsRLCharacterization of a new cytotoxin that contributes to Staphylococcus aureus pathogenesisMol Microbiol20117981482521255120
  • MalachowaNKobayashiSDBraughtonKRStaphylococcus aureus leukotoxin GH promotes inflammationJ Infect Dis20122061185119322872735
  • MorinagaNKaihouYNodaMPurification, cloning and characterization of variant LukE-LukD with strong leukocidal activity of staphylococcal bi-component leukotoxin familyMicrobiol Immunol200347819012636257
  • AlonzoF3rdKozhayaLRawlingsSACCR5 is a receptor for Staphylococcus aureus leukotoxin EDNature2013493515523235831
  • LiMDuXVillaruzAEMRSA epidemic linked to a quickly spreading colonization and virulence determinantNat Med20121881681922522561
  • DeLeoFRKennedyADChenLMolecular differentiation of historic phage-type 80/81 and contemporary epidemic Staphylococcus aureusProc Natl Acad Sci USA2011108180911809622025717
  • MwangiMMWuSWZhouYTracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencingProc Natl Acad Sci USA20071049451945617517606
  • HowdenBPStinearTPAllenDLJohnsonPDWardPBDaviesJKGenomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureusAntimicrob Agents Chemother2008523755376218644967
  • HowdenBPMcEvoyCRAllenDLEvolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKRPLoS Pathog20117e100235922102812
  • GaoWChuaKDaviesJKTwo novel point mutations in clinical Staphylococcus aureus reduce linezolid susceptibility and switch on the stringent response to promote persistent infectionPLoS Pathog20106e100094420548948
  • McAdamPRHolmesATempletonKEFitzgeraldJRAdaptive evolution of Staphylococcus aureus during chronic endobronchial infection of a cystic fibrosis patientPLoS One20116e2430121912685
  • UhlemannACKennedyADMartensCPorcellaSFDeLeoFRLowyFDToward an understanding of the evolution of Staphylococcus aureus strain USA300 during colonization in community householdsGenome Biol Evol201241275128523104992
  • YoungBCGolubchikTBattyEMEvolutionary dynamics of Staphylococcus aureus during progression from carriage to diseaseProc Natl Acad Sci USA20121094550455522393007
  • WertheimHFVosMCBoelensHALow prevalence of methicillin-resistant Staphylococcus aureus (MRSA) at hospital admission in the Netherlands: the value of search and destroy and restrictive antibiotic useJ Hosp Infect20045632132515066745
  • VosMCOttAVerbrughHASuccessful search-and-destroy policy for methicillin-resistant Staphylococcus aureus in the NetherlandsJ Clin Microbiol2005432034 author reply 2034–203515815056
  • GravelandHWagenaarJAHeesterbeekHMeviusDvan DuijkerenEHeederikDMethicillin resistant Staphylococcus aureus ST398 in veal calf farming: human MRSA carriage related with animal antimicrobial usage and farm hygienePLoS One20105e1099020544020
  • KallenAJMuYBulensSHealth care-associated invasive MRSA infections, 2005–2008JAMA201030464164820699455
  • JohnsonAPDaviesJGuyRMandatory surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in England: the first 10 yearsJ Antimicrob Chemother20126780280922223229
  • WyllieDHWalkerASMillerRDecline of meticillin-resistant Staphylococcus aureus in Oxfordshire hospitals is strain- specific and preceded infection-control intensificationBMJ Open20111e000160